scispace - formally typeset
C

Cedric Mombereau

Researcher at Novartis

Publications -  19
Citations -  3816

Cedric Mombereau is an academic researcher from Novartis. The author has contributed to research in topics: GABAB receptor & Metabotropic receptor. The author has an hindex of 16, co-authored 18 publications receiving 3520 citations. Previous affiliations of Cedric Mombereau include University of Pennsylvania & Hoffmann-La Roche.

Papers
More filters
Journal ArticleDOI

The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice.

TL;DR: The tail suspension test is a useful test for assessing the behavioural effects of antidepressant compounds and other pharmacological and genetic manipulations relevant to depression.
Journal ArticleDOI

In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.

TL;DR: It is suggested that it is prudent and most appropriate to use convergent tests that draw on different antidepressant-related endophenotypes, and complimentary physiological analyses in order to provide a program of information concerning whether a given phenotype is functionally relevant to depression-related pathology.
Journal ArticleDOI

Genetic and Pharmacological Evidence of a Role for GABA B Receptors in the Modulation of Anxiety- and Antidepressant-Like Behavior

TL;DR: Positive modulation of the GABAB receptors may serve as a novel therapeutic strategy for the development of anxiolytics, whereas GABAB receptor antagonism may service as a basis for the generation of novel antidepressants.
Journal ArticleDOI

A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo.

TL;DR: An mGluR7-selective agonist, N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), which directly activates receptor signaling via an allosteric site in the transmembrane domain is characterized and provided evidence for full agonist activity mediated by the heptahelical domain of family 3 G protein-coupled receptors that may lead to drug development opportunities.